Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 3/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.37 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | BACE1 | P56817 | 2/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.37 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16408429 | 0.90 | APP (0.41) | APPPTPN1PPARGNR1H4PPARA | |
| SCHEMBL16406497 | 0.81 | ALOX5 (0.39) | PPARGNR1H4PPARABACE1MAOB | |
| SCHEMBL16406485 | 0.79 | APP (0.45) | APPPTPN1NR1H4BACE1MAOB | |
| SCHEMBL16406489 | 0.71 | APP (0.38) | APPPTPN1NR1H4BACE1MAOB | |
| SCHEMBL16408430 | 0.71 | ALOX5 (0.38) | MAOBALOX5 | |
| SCHEMBL16406492 | 0.70 | APP (0.44) | APPPTPN1NR1H4BACE1MAOB | |
| SCHEMBL16406491 | 0.69 | ALOX5 (0.42) | APPPTPN1NR1H4BACE1MAOB | |
| SCHEMBL21973056 | 0.68 | ALOX5 (0.38) | APPPPARGPPARAPPARDDNMT1 | |
| SCHEMBL21972849 | 0.68 | ALOX5 (0.35) | MAOBALOX5 | |
| SCHEMBL16406487 | 0.67 | ALOX5 (0.39) | APPPTPN1NR1H4BACE1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216987-B2 | Chroman derivative | TMS CO., LTD. (JP) | 2015-12-22 | — | — | US | disclosed |
| US-20150025251-A1 | CHROMAN DERIVATIVE | TMS CO., LTD. (JP) | 2015-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025251-A1 | CHROMAN DERIVATIVE | CDYL, CNOT1, CNPY2 | APP 2822/4885PTPN1 1700/4885PPARG 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.